Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 11/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 6/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25219174 | 1.00 | MAPK1 (0.37) | MAPK1TLR9TLR8TLR7LRRK2 | |
| SCHEMBL25219176 | 1.00 | MAPK1 (0.37) | MAPK1TLR9TLR8TLR7LRRK2 | |
| SCHEMBL30251981 | 0.87 | TLR9 (0.36) | MAPK1TLR9TLR8TLR7LRRK2 | |
| SCHEMBL23884432 | 0.87 | TLR9 (0.36) | MAPK1TLR9TLR8TLR7LRRK2 | |
| SCHEMBL23906073 | 0.87 | TLR9 (0.36) | MAPK1TLR9TLR8TLR7LRRK2 | |
| SCHEMBL23906173 | 0.87 | LRRK2 (0.37) | MAPK1TLR9TLR8TLR7LRRK2 | |
| SCHEMBL30251796 | 0.87 | LRRK2 (0.37) | MAPK1TLR9TLR8TLR7LRRK2 | |
| SCHEMBL25215968 | 0.84 | RXRA (0.36) | MAPK1TLR9TLR8TLR7 | |
| SCHEMBL25215970 | 0.84 | RXRA (0.36) | MAPK1TLR9TLR8TLR7 | |
| SCHEMBL30251749 | 0.84 | RXRA (0.36) | MAPK1TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| WO-2021203025-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINE1, SERPINA3 | MAPK1 1660/4885TLR9 4866/4885TLR8 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.